ArticleThe Lancet. Infectious diseases2021
Optimism and caution for an inactivated COVID-19 vaccine.
Article in The Lancet. Infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Heterologous prime-boost strategies for COVID-19 vaccines.Journal of travel medicine · 2022Review
- Effectiveness of Inactivated COVID-19 Vaccines Against Illness Caused by the B.1.617.2 (Delta) Variant During an Outbreak in Guangdong, China : A Cohort Study.Annals of internal medicine · 2022Observational
- Economic evaluations of inactivated COVID-19 vaccines in six Western Pacific and South East Asian countries and regions: A modeling study.Infectious Disease Modelling · 2022Article
- Selection and T-cell antigenicity of synthetic long peptides derived from SARS-CoV-2.The Journal of general virology · 2022Article
- Inactivated SARS-CoV-2 vaccine (BBV152)-induced protection against symptomatic COVID-19.Lancet (London, England) · 2021Article
- Sterilizing Immunity against COVID-19: Developing Helper T cells I and II activating vaccines is imperative.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- Three-Dimensional Cell Cultures as a Research Platform in Lung Diseases and COVID-19.Tissue engineering and regenerative medicine · 2021Review
- Review
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.